New findings from a pre-specified analysis of DELIVER Phase III trial data show that AstraZeneca’s Farxiga (dapagliflozin) improved symptom burden and health-related quality of life in patients with heart failure (HF) and mildly reduced or preserved ejection fraction (EF) compared with placebo1. The results were presented today at the American Heart Association (AHA) Scientific Sessions 2022 in Chicago, Illinois, US, and are currently in press in the Journal of the American College of Cardiology.
- Read more about Farxiga improved symptom burden in heart failure
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/farxiga-improved-symptom-burden-in-heart-failure
No comments:
Post a Comment